Ries M, Zenker M, Klinge J, Keuper H, Harms D
Klinik mit Poliklinik für Kinder und Jugendliche, Universität Erlangen-Nürnberg, Germany.
J Pediatr Hematol Oncol. 1995 Aug;17(3):260-4. doi: 10.1097/00043426-199508000-00008.
The fibrinolytic system is involved in a wide variety of biological phenomena and differs physiologically in newborns compared to older children or adults. Because the newborn has hypoplasminogenemia and a possible existence of a dysfunctional plasminogen with normal adult levels of plasminogen activator inhibitor type 1 and alpha 2-antiplasmin and elevated levels of plasminogen activator inhibitor type 2, it could be expected that the response to standard concentrations and doses of plasminogen activators would be reduced.
We have studied the kinetics of in vitro fibrinolysis after adding different concentrations of streptokinase(SK), urokinase(UK), and recombinant tissue plasminogen activator(rt-PA) by use of a microtiter clot lysis assay.
Geometrical dilution rows showed characteristic dose response curves. After clot formation a rapid lysis was seen with all plasminogen activators. The 50% lysis time correlated to the plasminogen activator dose and showed no differences among normal adults, children aged 1-6 years, and children age 7-14 years. Newborns demonstrated a significantly prolonged 50% lysis time with all urokinase concentrations. The 50% lysis time with recombinant tissue plasminogen activator and streptokinase was significantly prolonged only at high concentrations, whereas we could not see any differences at lower concentrations.
The experience with thrombolytic agents in newborns is limited, and no controlled investigations have been reported. Our results of the fibrinolytic potential in a plasma milieu in vitro after adding different plasminogen activators can be helpful to establish dosage guidelines for thrombolytic therapy in newborns and older children.
纤维蛋白溶解系统参与多种生物学现象,与大龄儿童或成人相比,新生儿的生理情况有所不同。由于新生儿存在低纤溶酶原血症,且可能存在功能异常的纤溶酶原,同时成人水平的纤溶酶原激活物抑制剂1和α2 -抗纤溶酶正常,而纤溶酶原激活物抑制剂2水平升高,因此可以预期新生儿对标准浓度和剂量的纤溶酶原激活剂的反应会降低。
我们通过微量滴定凝块溶解试验,研究了添加不同浓度的链激酶(SK)、尿激酶(UK)和重组组织型纤溶酶原激活剂(rt - PA)后体外纤维蛋白溶解的动力学。
几何稀释系列显示出特征性的剂量反应曲线。凝块形成后,所有纤溶酶原激活剂均可见快速溶解。50%溶解时间与纤溶酶原激活剂剂量相关,在正常成人、1 - 6岁儿童和7 - 14岁儿童之间无差异。所有尿激酶浓度下,新生儿的50%溶解时间均显著延长。仅在高浓度时,重组组织型纤溶酶原激活剂和链激酶的50%溶解时间显著延长,而在低浓度时未见差异。
新生儿溶栓药物的经验有限,尚无对照研究报道。我们添加不同纤溶酶原激活剂后体外血浆环境中纤维蛋白溶解潜能的结果,有助于制定新生儿和大龄儿童溶栓治疗的剂量指南。